JDD

Glycopyrronium Tosylate Cloth for Hyperhidrosis Therapeutic Cheat Sheet
Qbrexza Therapeutic Cheat Sheet
by Blair Allais, MD on
Hyperhidrosis affects approximately 4.8% of the U.S. population1 and causes patients significant psychosocial distress. Patients are looking to maximize non-invasive treatment options while avoiding systemic side effects. We continue our series, Therapeutic Cheat Sheet, with a closer look at glycopyrronium tosylate cloths. [caption id="attachment_11862" align="alignleft" width="1934"] Click ima …
Understanding and Changing Patient Behavior and Minimizing Risk of UV Damage – A JDD Podcast Recap
UV damage
by James J. Contestable, MD on
We all discuss sun protection with our patients.  At this point, our recommendations are predictable – “avoidance, protective clothing, SPF 30+, broad-spectrum, water-resistant, and reapplication.” But how can we effectively change patient behavior? Important note – this discussion has wide arching correlations to all areas of human behavior, medicine, and dermatology that spans more th …
JDD November Issue Highlights: Lasers, Light Sources, and Devices
JDD November 2020 Issue Highlights
by NEXT STEPS IN DERM TEAM on
The November issue of the Journal of Drugs in Dermatology focuses on the topics of Lasers, Light Sources, and Devices, featuring an outstanding line-up of original articles. Straight from the JDD Editor’s desk, we share this month’s issue highlights The Guest Editorial by Dr. Macrene Alexiades focuses on the growing body of objective quantifiable data demonstrating time-sensitive improvemen …
JDD September Issue Highlights
by NEXT STEPS IN DERM TEAM on
Below are the issue highlights for the September issue of the JDD. Randomized, Double-Blinded, Split-Face Study Comparing the Efficacy and Tolerability of Two Topical Products in Melasma compares a HQ-free, retinol-free cosmetic topical brightener and HQ 4% in patients with skin types III-VI. Complication of Soft Tissue Fillers: Prevention and Management Review highlights the various advers …
Widespread Skin Necrosis Secondary to Gemcitabine Therapy
Skin Necrosis
by NEXT STEPS IN DERM TEAM on
INTRODUCTION Cutaneous side effects are relatively common in chemotherapy but vary in frequency and severity depending on the medication, dose, duration, pharmacokinetics, and pharmacodynamics. Gemcitabine, a pyrimidine nucleoside analogue, is a common oncologic agent used in the treatment of a variety of malignancies such as cancers of the head and neck, lung cancer, breast cancer, pancreatic …